Ethnopharmacological relevance Traditional Chinese medicine (TCM) has demonstrated multiple therapeutic advantages in colorectal cancer (CRC) management. The herbal formula Fuzheng Shengbai Decoction (FZSB) has been widely used in clinical practice with well-documented therapeutic efficacy; nevertheless, the mechanisms underlying its anti-CRC effects remain largely unexplored. Aim of the study To evaluate the therapeutic efficacy of FZSB in colorectal cancer and its potential underlying mechanisms. Materials and Methods Through both clinical and experimental studies, the therapeutic efficacy and underlying mechanisms of FZSB in colorectal cancer were investigated. A clinical cohort of postoperative CRC patients and BALB/c mouse xenograft models were used to evaluate its immunomodulatory and antitumor effects. RIP-qPCR, MeRIP-qPCR, and MeRIP-seq were employed to explore the potential molecular mechanisms of FZSB. Molecular docking was performed to assess the interactions between active components of FZSB and key targets. Results FZSB significantly inhibited CRC growth and proliferation both in vivo and in vitro. In the clinical cohort, FZSB elevated the CD4 + /CD8 + T-cell ratio. In xenograft models, FZSB increased CD8 + T-cell infiltration, proportion, and activation, and upregulated the tumor suppressor CLCA2, which was positively correlated with prognosis. Mechanistically, FZSB stabilized YTHDC2, promoting m 6 A-dependent CLCA2 mRNA stabilization and expression. Molecular docking indicated that multiple FZSB bioactive compounds could interact favorably with YTHDC2 and CLCA2. Conclusions FZSB enhances anti–colorectal cancer immune responses and is associated with increased CD8 + T-cell activation, while concurrently modulating the YTHDC2–CLCA2 axis via m 6 A -mediated mRNA stabilization.